In body 720 body composition analyser

Body weight outcomes and glycaemic and cardiometabolic risk factors were measured repeatedly at 8, 26, 52, 104, and 156 weeks. Body weight was measured in fasting (>10 h) participants with light clothing or underwear. Fat mass was determined using dual energy x-ray absorptiometry (DEXA) in the UK (GE Lunar Prodigy, GE Healthcare, Madison, WI, USA), Australia (Hologic Discovery W, Hologic, Bedford, MA, USA), and New Zealand (GE Lunar, GE Healthcare, Madison, WI, USA) and bioelectrical impedance in Finland (InBody720 Body Composition Analyser, Biospace Co., Ltd, Korea). Blood samples were drawn from the antecubital vein after fasting (>10 h) and were initially stored locally at À80 C. Then they were sent to the central laboratory in Finnish Institute for Health and Welfare, Helsinki, Finland for batch analysis of FPG, haemoglobin A 1c (HbA 1c ), fasting insulin, fasting triacylglycerols, total cholesterol, and HDL-cholesterol. HOMA-IR was calculated as fasting insulin (mU$L À1 ) Â FPG (mmol$L À1 )/22.5. The triacylglycerol-glucose (TyG) index, a measure reflecting insulin resistance and predicting the development of CVD, was calculated as Ln [triacylglycerols (mg$dL À1 ) Â FPG (mg$dL À1 )/2] [28].